Back to Search
Start Over
D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells
- Source :
- Zhang, L, Sorensen, M D, Kristensen, B W, Reifenberger, G, McIntyre, T M & Lin, F 2018, ' D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells ', Clinical Cancer Research, vol. 24, no. 21, pp. 5381-5391 . https://doi.org/10.1158/1078-0432.CCR-17-3855
- Publication Year :
- 2018
-
Abstract
- Purpose: Somatic mutations in the isocitrate dehydrogenase (IDH)-1 and -2 genes are remarkably penetrant in diffuse gliomas. These highly effective gain-of-function mutations enable mutant IDH to efficiently metabolize isocitrate to D-2-hydroxyglutarate (D 2-HG) that accumulates to high concentrations within the tumor microenvironment. D 2-HG is an intracellular effector that promotes tumor growth through widespread epigenetic changes in IDH-mutant tumor cells, but its potential role as an intercellular immune regulator remains understudied. Experimental Design: Complement activation and CD4+, CD8+, or FOXP3+ T-cell infiltration into primary tumor tissue were determined by immunohistochemistry using sections from 72 gliomas of World Health Organization (WHO) grade III and IV with or without IDH mutations. Ex vivo experiments with D 2-HG identified immune inhibitory mechanisms. Results: IDH mutation associated with significantly reduced complement activation and decreased numbers of tumor-infiltrating CD4+ and CD8+ T cells with comparable FOXP3+/CD4+ ratios. D 2-HG potently inhibited activation of complement by the classical and alternative pathways, attenuated complement-mediated glioma cell damage, decreased cellular C3b(iC3b) opsonization, and impaired complement-mediated phagocytosis. Although D 2-HG did not affect dendritic cell differentiation or function, it significantly inhibited activated T-cell migration, proliferation, and cytokine secretion. Conclusions: D 2-HG suppresses the host immune system, potentially promoting immune escape of IDH-mutant tumors. Clin Cancer Res; 24(21); 5381–91. ©2018 AACR.
- Subjects :
- 0301 basic medicine
Cytotoxicity, Immunologic
Cancer Research
medicine.medical_treatment
T-Lymphocytes
Dendritic cell differentiation
Lymphocyte Activation
Article
Glutarates
03 medical and health sciences
Immune system
Phagocytosis
Cell Movement
Cell Line, Tumor
medicine
Tumor Microenvironment
Humans
Complement Activation
Tumor microenvironment
Chemistry
FOXP3
Complement System Proteins
Dendritic Cells
Glioma
Isocitrate Dehydrogenase
Complement system
030104 developmental biology
Isocitrate dehydrogenase
Cytokine
Oncology
Astrocytes
Mutation
Cancer research
iC3b
Neoplasm Grading
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Zhang, L, Sorensen, M D, Kristensen, B W, Reifenberger, G, McIntyre, T M & Lin, F 2018, ' D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells ', Clinical Cancer Research, vol. 24, no. 21, pp. 5381-5391 . https://doi.org/10.1158/1078-0432.CCR-17-3855
- Accession number :
- edsair.doi.dedup.....f701ec3c57438793b028f8def12dfc12